Osteopenia is a condition in which bone mineral density is below the normal range for a young adult but has not yet reached the threshold that defines osteoporosis. The term comes from the World Health Organization’s classification system for bone density measured on DEXA scanning: a T-score between −1.0 and −2.5. While osteopenia is sometimes dismissed as simply a precursor or “pre-disease” state, it is more accurately understood as a point on a continuum — a signal that bone density is lower than it should be and that the risk of fragility fracture, though lower than in osteoporosis, is meaningfully elevated above the normal baseline. Millions of adults in the UK have osteopenia and are unaware of it, which is precisely why understanding what it means — and what to do about it — matters.
What Is Osteopenia?
Bone mineral density is measured by DEXA scanning and expressed as a T-score — a comparison between the individual’s measured bone density and the average bone density of a healthy young adult at peak bone mass. The T-score represents the number of standard deviations above or below that reference population:
- Normal: T-score at or above −1.0
- Osteopenia: T-score between −1.0 and −2.5
- Osteoporosis: T-score at or below −2.5
The WHO developed these thresholds in 1994 specifically for postmenopausal women; their application to men and premenopausal women is less straightforward, and the Z-score — which compares bone density to age-matched peers rather than young adults — is preferred in those groups. The T-score thresholds are best understood as population-based risk categories rather than absolute diagnostic lines: a woman with a T-score of −2.4 does not have a categorically different bone condition from one with a T-score of −2.6, but the WHO classification gives clinicians and patients a common language for risk communication.
Osteopenia is extremely common. In the United States, an estimated 43% of postmenopausal women have osteopenia at the hip. UK prevalence is similarly high, with the proportion increasing substantially with age. By the time a woman reaches her 70s, most will have T-scores in the osteopenia range or lower. For context on how this density is measured, see our guide to bone density test: a simple guide.
Osteopenia vs. Osteoporosis
The distinction between osteopenia and osteoporosis is a threshold on a continuous scale — not a qualitative difference in the nature of the underlying bone problem. Both represent below-normal bone density that increases fracture risk compared with a person whose T-score is in the normal range. The differences are quantitative:
- Fracture risk is meaningfully elevated in osteopenia, though lower than in osteoporosis
- Osteoporosis carries the higher absolute fracture probability — particularly for hip and vertebral fractures
- The FRAX tool (WHO fracture risk calculator) captures this graded risk: it uses the actual T-score value, not just which category it falls into, to calculate 10-year fracture probability
- Many fragility fractures in absolute terms occur in people with osteopenia rather than osteoporosis — because osteopenia is far more prevalent, meaning more people are at moderately elevated risk
In practice, this means osteopenia deserves attention — not panic, but awareness and active management of modifiable risk factors. Full detail on osteoporosis is in our guide to osteoporosis: symptoms, causes, and prevention.
Causes and Risk Factors
Osteopenia develops when bone loss outpaces bone formation — the same fundamental imbalance that causes osteoporosis, occurring earlier on the spectrum. The principal causes and risk factors are:
Age and menopause: Peak bone mass is reached in the mid-to-late twenties. From the early thirties, gradual bone loss begins in both sexes. In women, oestrogen at menopause suppresses osteoclast (bone-resorbing cell) activity; when oestrogen levels fall at menopause, osteoclasts become more active and bone loss accelerates to up to 3% per year in the first five to ten post-menopausal years. Early menopause — before age 45 — and surgical menopause (oophorectomy) carry higher risk because they extend the years of oestrogen-deficient bone loss. In men, testosterone decline with age contributes to gradual bone loss, though the trajectory is less steep than female postmenopausal loss.
Dietary and lifestyle factors:
- Low calcium intake — calcium is the primary structural mineral in bone
- Vitamin D deficiency — essential for intestinal calcium absorption; deficiency is extremely common in UK adults, particularly in winter months
- Smoking — directly impairs osteoblast (bone-forming cell) function and reduces calcium absorption
- Excess alcohol — inhibits osteoblast function and increases fall risk
- Low body weight or BMI below 19 — reduced mechanical loading and reduced adipose-derived oestrogen in postmenopausal women
- Physical inactivity — weight-bearing exercise is the primary mechanical stimulus for osteoblast activity
Medical conditions and medications: Secondary causes of low bone density include coeliac disease (impaired calcium absorption), inflammatory bowel disease, rheumatoid arthritis, hyperthyroidism, hyperparathyroidism, eating disorders (anorexia), and hypogonadism. Glucocorticoids (steroids) are the most common medication cause — prednisolone at 5 mg/day for three months or longer significantly suppresses osteoblast function. Other relevant medications include aromatase inhibitors (used in breast cancer treatment), androgen deprivation therapy (prostate cancer), and long-term proton pump inhibitors.
Does Osteopenia Progress to Osteoporosis?
Osteopenia does not inevitably progress to osteoporosis — this is an important distinction that the framing of osteopenia as a “precursor” can obscure. The rate of bone loss varies considerably between individuals, and with appropriate lifestyle intervention the progression from osteopenia toward osteoporosis can be significantly slowed or even stabilised. Research published in the Journal of Bone and Mineral Research and other studies has shown that a large proportion of postmenopausal women with osteopenia retain T-scores in the osteopenia range for years without crossing the osteoporosis threshold, particularly if calcium and vitamin D intake is adequate and they remain physically active.
The factors that accelerate progression from osteopenia to osteoporosis include: continuing oestrogen deficiency (years since menopause), very low initial T-score (close to −2.5), active secondary causes (ongoing glucocorticoid use, untreated malabsorption), low calcium and vitamin D intake, physical inactivity, and smoking. Addressing modifiable risk factors is the most clinically meaningful response to an osteopenia diagnosis.
Who Should Be Tested?
DEXA scanning to identify osteopenia is recommended by NICE for several groups:
- Women aged 65 and over (routine)
- Women aged 50–64 with clinical risk factors: early menopause, prior fragility fracture, family history of hip fracture, glucocorticoid use, low BMI, or secondary causes
- Men aged 70 and over, or men 50–69 with significant risk factors
- Any adult who has sustained a fragility fracture
- Anyone starting long-term glucocorticoid treatment (prednisolone ≥5 mg/day for ≥3 months)
The FRAX tool (developed by the University of Sheffield for the WHO) can be used before DEXA to calculate 10-year fracture probability from clinical risk factors alone, helping clinicians identify which patients need DEXA and which are at low enough risk that scanning would not change management. Detail on the scan itself is in our guide to DEXA scan: what adults should know.
What to Do If You Have Osteopenia
For most adults with osteopenia, the management approach is lifestyle optimisation rather than pharmacological treatment, unless fracture risk assessment identifies high overall fracture probability.
Calcium and diet: Aim for 700–1,000 mg of calcium per day from dietary sources — dairy products, fortified plant milks, green leafy vegetables (broccoli, kale), canned fish with bones (sardines, salmon), and calcium-set tofu. Supplemental calcium is appropriate when dietary intake is consistently low, but should be taken with vitamin D. Comprehensive guidance on dietary sources and supplementation is in our guide to calcium and bone health.
Vitamin D: Ensure adequate vitamin D status — the UK government recommends 400 IU/day supplementation for all adults, rising to 800–1,000 IU/day for those over 65 or with documented deficiency. Vitamin D is essential for calcium absorption and plays a direct role in bone mineralisation. More on this is in our guide to vitamin D and bone health.
Exercise: Weight-bearing aerobic exercise (walking, jogging, dancing, tennis) and resistance training (weights, resistance bands) both maintain and in some cases modestly improve bone density. Exercise programmes targeting hip and spine are most relevant for osteopenia management. At least 150 minutes of moderate aerobic activity plus two resistance sessions per week is the standard recommendation. Balance exercises additionally reduce fall risk.
Lifestyle measures: Stop smoking if applicable, limit alcohol to no more than 14 units per week, maintain a healthy body weight, and optimise management of any medical conditions contributing to bone loss (particularly coeliac disease, thyroid disorders, and inflammatory conditions).
When is medication appropriate? Bisphosphonate treatment is not routinely indicated for osteopenia alone. However, NICE guidance recommends considering pharmacological treatment for individuals with osteopenia whose FRAX score indicates a 10-year major fracture probability above the intervention threshold — typically those with additional clinical risk factors, prior fragility fracture, or T-scores approaching −2.5 with other risk factors. The decision is made by combining the DEXA result with the full clinical picture, not by the T-score category alone.
Osteopenia After Cancer Treatment
Cancer treatment is an increasingly recognised cause of osteopenia and osteoporosis, and one that affects a growing number of adults as cancer survival rates improve. The two main oncological causes are:
Aromatase inhibitors (anastrozole, letrozole, exemestane) are standard adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women. They reduce circulating oestrogen to very low levels, removing the remaining oestrogenic protection on bone that persists even after menopause. Studies show that one to two years of aromatase inhibitor therapy can reduce hip bone mineral density by 3–5%, with significant T-score decline — many women who start treatment in the osteopenia range progress to osteoporosis over a five-year course. NICE guidance recommends baseline and monitoring DEXA for all women starting aromatase inhibitors, with bisphosphonate co-prescription for those with baseline osteoporosis and consideration for those with osteopenia and additional risk factors.
Androgen deprivation therapy (ADT) — used in the treatment of prostate cancer — suppresses testosterone production, which has an indirect but significant effect on bone density in men. Testosterone is converted peripherally to oestrogen, which is the primary bone-protective hormone in both sexes. Testosterone deprivation therefore also means oestrogen deprivation at the bone level. Studies show that men on continuous ADT lose approximately 2–3% of bone density per year, and the prevalence of osteopenia and osteoporosis is significantly higher in men who have received ADT than in age-matched controls. Bisphosphonate or denosumab co-prescription is recommended for men with osteoporosis on ADT, with DEXA-guided monitoring for those with osteopenia.
Other oncological causes include direct effects of chemotherapy on osteoblast function, corticosteroid use as anti-emetic or anti-inflammatory therapy in cancer treatment protocols, and premature menopause from ovarian toxicity of chemotherapy in younger women. Anyone who has received cancer treatment and has not had a bone density assessment should discuss whether DEXA screening is appropriate with their oncologist or GP.
Monitoring Osteopenia
A single DEXA scan at diagnosis establishes a baseline. Repeat scanning is generally appropriate at two to three year intervals in those with osteopenia and active risk factors, or at three to five years in those with T-scores near the upper end of the osteopenia range and few additional risk factors. More frequent scanning (annually) is not usually recommended — bone density changes slowly, and annual scans do not provide meaningfully different information in most cases. If a fracture occurs between scans, reassessment is warranted regardless of interval. Monitoring should also consider bone turnover markers (CTX for resorption, P1NP for formation) in selected cases — these blood tests change faster than bone density and can help gauge whether a lifestyle or treatment programme is having the desired effect on bone metabolism before the next DEXA scan interval.
Frequently Asked Questions
Is osteopenia serious?
Osteopenia is a meaningful finding that warrants attention, but it should not be received as alarming. It means bone density is below the young-adult reference range and fracture risk is moderately elevated — it does not mean a fracture is inevitable, that osteoporosis is certain, or that pharmacological treatment is immediately required. For most adults with osteopenia and no other major risk factors, the appropriate response is a programme of lifestyle optimisation: adequate calcium and vitamin D, weight-bearing and resistance exercise, and smoking cessation. The concern about osteopenia is greatest when it coincides with other clinical risk factors — prior fracture, glucocorticoid use, very low BMI, secondary medical causes — which together may elevate overall fracture probability to the threshold at which medication is beneficial.
Can osteopenia be reversed?
T-scores in the osteopenia range can improve — particularly in younger postmenopausal women who are still close to peak bone mass and who adopt consistent exercise and dietary programmes. Resistance training is the single most effective non-pharmacological intervention for improving bone mineral density. However, the more realistic goal for most adults with osteopenia is stabilisation — preventing further loss — rather than clinically significant reversal. A T-score that remains stable in the osteopenia range over five to ten years of follow-up represents a successful outcome. Pharmacological treatment (bisphosphonates, denosumab) can improve T-scores in osteopenia, but is generally reserved for those at higher overall fracture risk, as the absolute benefit does not outweigh medication risks and side effects in lower-risk individuals.
What is the difference between a T-score and a Z-score?
The T-score compares your bone mineral density to the average of a healthy young adult at peak bone mass (typically a 30-year-old woman for females). It is the score used to classify osteopenia and osteoporosis. The Z-score compares your bone density to an age-matched and sex-matched peer group — people the same age and sex as you. The Z-score is used in premenopausal women, men under 50, and children, where comparing to young adults would be misleading (bone density naturally declines with age, so a Z-score below −2.0 in an older person is more clinically significant than the same T-score would suggest). In postmenopausal women, both scores are usually reported; in clinical practice, the T-score drives diagnosis and treatment decisions.
Does osteopenia cause symptoms?
Osteopenia itself causes no symptoms. Like osteoporosis, it is an entirely silent condition — bone loss occurs without pain, aching, or any perceptible change. The condition is detectable only through DEXA scanning. Symptoms arise only if a fracture occurs, and even then, vertebral compression fractures — common in low bone density states — may cause only mild back discomfort that is easily attributed to muscle strain rather than a fracture. This silence is precisely why DEXA screening matters: waiting for symptoms means waiting for a fracture, which is the harm that osteopenia management seeks to prevent.
Does osteopenia always lead to osteoporosis?
No. Osteopenia does not inevitably progress to osteoporosis. Many people remain in the osteopenia T-score range throughout their lives without crossing the −2.5 threshold, particularly when lifestyle factors are well managed. The rate of bone loss varies significantly between individuals, and the years since menopause, medication history, nutritional status, and physical activity level all influence the trajectory. The most pessimistic scenario — rapid progression to osteoporosis with fractures — is more likely in those who continue smoking, have active secondary causes (untreated malabsorption, ongoing steroids), have very low initial T-scores (e.g., −2.3 at age 55), or have multiple additional clinical risk factors. Addressing those factors changes the trajectory meaningfully.
Should I take calcium and vitamin D supplements if I have osteopenia?
The evidence supports ensuring adequate calcium and vitamin D intake — whether through diet or supplementation — for anyone with osteopenia, as deficiency of either is a modifiable driver of ongoing bone loss. Dietary calcium is preferable to supplements where achievable. If dietary intake consistently falls below 700 mg per day, a supplement of 500–600 mg elemental calcium (not more — higher doses provide no additional benefit and have been associated with cardiovascular concerns in some studies) combined with vitamin D is appropriate. Vitamin D supplementation (400–800 IU/day) is recommended for most UK adults regardless of bone health, given the limited winter sunlight at UK latitudes. These nutritional measures are important baseline support — they do not replace, but do reinforce, the benefits of weight-bearing exercise.
Which exercises are best for osteopenia?
The most effective exercises for bone health in osteopenia combine weight-bearing aerobic activity with progressive resistance training. For bone density specifically, impact activities — jogging, skipping, tennis, aerobics — that produce ground-reaction forces through the skeleton are the most direct bone-building stimulus, and are appropriate for adults with osteopenia who have no existing fractures. Brisk walking is weight-bearing and beneficial, though less osteogenic than higher-impact activities. Resistance training using weights or resistance bands is the most consistently evidence-supported intervention for improving BMD at the hip and spine specifically, and should be included two to three times per week. Swimming and cycling, while excellent for cardiovascular fitness, are non-weight-bearing and do not contribute meaningfully to bone density. Balance exercises (tai chi, single-leg standing) reduce fall risk independently of their effect on bone density.
Summary
Osteopenia — T-score between −1.0 and −2.5 — is a very common finding in adults over 50, particularly postmenopausal women, and represents below-normal bone density with moderately elevated fracture risk. It is not a disease requiring pharmacological treatment in most cases, but a signal that lifestyle optimisation is important: adequate calcium and vitamin D intake, regular weight-bearing and resistance exercise, smoking cessation, and management of secondary causes where relevant. Pharmacological treatment is appropriate when overall fracture risk, assessed with FRAX and DEXA together, is high enough to make the benefit of treatment meaningful. Special attention to osteopenia is warranted for adults who have received cancer treatment — particularly aromatase inhibitors or androgen deprivation therapy — given the significant bone density loss associated with these treatments. DEXA monitoring at two to five year intervals tracks whether bone density is stable or declining over time. Early recognition and consistent lifestyle management gives the best chance of preventing progression to osteoporosis and avoiding the fragility fractures that are the disease’s major clinical harm. The condition is closely related to osteoporosis and bone density — both covered in detail in our guides to osteoporosis: symptoms, causes, and prevention and bone density: what it means.
Medical disclaimer: This article is for general educational purposes and does not constitute medical advice. Consult a qualified healthcare professional for personalised assessment of osteopenia and fracture risk.
References:
NHS. Osteoporosis. NHS. 2023.
NICE CG146. Osteoporosis: assessing the risk of fragility fracture. NICE. 2017 (updated 2023).
WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. 1994.
Siris ES, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108–1112.
Royal Osteoporosis Society. Clinical guidance for the effective identification of vertebral fractures. theros.org.uk. 2023.
I was told I had osteopenia after a DEXA scan at age 56 — T-score of −1.7 at the lumbar spine. My GP said it wasn’t osteoporosis yet and I didn’t need medication, but she recommended increasing my calcium intake, starting vitamin D supplementation, and adding weight-bearing exercise to my routine. I started a twice-weekly gym class that combines aerobics with light weights, and I take a daily walk of 40 minutes. At my follow-up DEXA two years later my T-score was −1.6 — a modest improvement, but my GP said the most important thing was that it hadn’t worsened. The article’s point about stabilisation being the realistic goal for most people with osteopenia matches exactly what I was told. I found the explanation of why swimming doesn’t help bone density useful — I swim regularly and hadn’t realised it was essentially irrelevant for bone health.
Helen, your response to the lifestyle programme — stabilisation of T-score at −1.6 over two years — is precisely the outcome that evidence-based osteopenia management aims for. Stabilisation in the osteopenia range, rather than progression toward −2.5 and eventual osteoporosis, is the clinically meaningful success criterion for most postmenopausal women at your fracture risk level. The combination of weight-bearing aerobic exercise plus resistance training is the most evidence-supported non-pharmacological intervention available, and your twice-weekly combined class plus daily walking aligns well with current recommendations. On swimming: the mechanical mechanism of bone formation requires ground-reaction forces transmitted through the skeleton — swimming unloads the skeleton in water, meaning those forces are absent. It remains excellent for cardiovascular and muscle fitness, but it does not substitute for weight-bearing activity in a bone health programme. James, your case illustrates precisely why oncologists now routinely incorporate bone health monitoring into prostate cancer follow-up. The testosterone-to-oestrogen conversion pathway means that ADT, by suppressing testosterone, simultaneously removes the primary bone-protective hormone (oestrogen) in men, creating a skeletal vulnerability that runs in parallel with the oncological treatment. Denosumab at the standard 60 mg every 6 months dose is an evidence-based choice for ADT-associated bone loss and has been shown in randomised trials to prevent the progression from osteopenia to osteoporosis in men on ADT.
I’m on androgen deprivation therapy for prostate cancer and was told at my last review that my DEXA showed osteopenia with a T-score of −1.9 after 18 months of ADT. My oncologist explained that this is expected with ADT but still needs to be managed. I’m now on denosumab injections every six months alongside the ADT, and I’ve been given a calcium and vitamin D supplement to take daily. The article’s section on cancer treatment-related osteopenia is something I wish I’d been able to read before starting treatment — knowing the mechanism (testosterone → oestrogen conversion in bone) would have helped me understand why the treatment that’s managing my cancer is also affecting my skeleton. It would have been useful context before the DEXA result came as a surprise.